Working with UKHSA's expertise

AI Summary

The UK Health Security Agency (UKHSA), specifically through its Vaccine Development and Evaluation Centre (VDEC), is inviting collaboration from industry, academia, and government sectors to address critical global health issues. This document serves as a partnership guide rather than a regulatory inspection report; consequently, specific inspection dates and violations are not applicable to this context. Instead, the focus is on leveraging UKHSA’s scientific expertise and operational excellence to accelerate the development of innovative health solutions. Key areas of collaboration include joint product development, clinical trials, technology development, and consultancy services. Notable successes highlighted include the rapid development of an immunoassay for Mpox during the 2022 global outbreak, ongoing research into maternal vaccines for Group B Streptococcus, and the creation of tools to combat antimicrobial resistance in Tuberculosis. The regulatory framework centers on public health impact and data-driven decision-making. To engage with these resources, interested organizations are required to contact the UKHSA Business Development team to discuss specific project needs and explore potential partnerships. This initiative aims to foster innovation and enhance collective responses to public health threats through shared expertise and access to world-class facilities.